Psychedelic medicine.

Big pharma is McDonald's serving hamburgers without owning a cow: it owns patents, never healing. A mushroom that grows for free is a threat until it becomes a patented molecule at $5,000 to $10,000 per treatment. The same industry branded weed a gateway drug while it flooded the world with opioids. There is exactly 1 gateway drug, and it is big pharma.

Oregon and Colorado roll out therapeutic psilocybin. The FDA panel rejected Lykos' MDMA treatment in 2024. Usona pushes psilocybin through the final trial phase with breakthrough status. Ibogaine is studied for addiction, PTSD and brain injuries. The money is racing ahead of the guardrails.

Psychedelics either transform mental health for millions, or become another patented luxury sold back to the desperate at $5,000 to $10,000 a treatment. I do not trust the referees, on the record since the COVID years, when cheap medicines got buried and the science got bought. I side with the healing, not the patent.

$10 billion by 2027 to 2028 on my call, as MDMA, psilocybin and lab-made variants move from underground ceremonies to corporate patents. What started as a movement to heal PTSD, depression and addiction has become a boardroom land grab.

Yes, psilocybin and MDMA delivered strong results in landmark trials. The science is no longer the question. A single dose of psilocybin lifted well-being for at least a year in the landmark studies. MDMA-assisted therapy took the majority of PTSD patients in final-phase trials below the diagnosis line. The US FDA still rejected MDMA therapy in August 2024 and asked for 1 more final-phase trial. Cannabis already produced an FDA-approved epilepsy medicine. Nature keeps passing its own tests.